Are Unapproved Over-the-Counter Animal Drugs Putting Public Health at Risk?

In December 2023, the U.S. Food and Drug Administration (FDA) took action by issuing nine Warning Letters to manufacturers and distributors of unapproved over-the-counter (OTC) antimicrobial animal drugs. These drugs were specifically intended for use in aquarium fish and birds. The FDA's move highlights the agency's ongoing commitment to promoting the responsible use of antimicrobials in animals.

The Warning Letters serve as a clear message from the FDA's Center for Veterinary Medicine (CVM) regarding the potential risks associated with the non-judicious use of antimicrobials. The FDA determined that these unapproved animal drugs, sold without a veterinarian's prescription, pose a significant threat. This is true even if the drugs are not intended for animals in the food production industry.

The FDA's concern primarily lies in the fact that these unapproved products contain medically important antimicrobials, which are crucial for treating human diseases. The Warning Letters specifically mention the presence of antimicrobials such as amoxicillin, azithromycin, cephalexin, and others. Each of these antimicrobials has been identified by the FDA as medically important for human health.

The CVM has been actively working for over a decade to promote the judicious use of antimicrobials in animals. Their efforts have aimed to slow down the development of antimicrobial resistance in humans by optimizing therapeutic effectiveness and reducing the selection of resistant microorganisms. In 2018, the CVM introduced a comprehensive 5-year action plan to support antimicrobial stewardship in veterinary settings.

As part of this plan, the CVM has encouraged sponsors to voluntarily change FDA-approved OTC animal drugs containing medically important antimicrobials to prescription status. The recent Warning Letters extend this initiative to unapproved drugs that contain antimicrobials significant for human health and are sold without proper veterinary oversight.

The FDA's actions underscore the importance of ensuring the safe and responsible use of antimicrobials in animals. By addressing the manufacturing and distribution of unapproved animal drugs, the FDA aims to protect public health and minimize the risks associated with antimicrobial resistance.

It is evident that stricter regulations and oversight are necessary to prevent the unauthorized use of medically important antimicrobials in animals. The FDA's efforts serve as a reminder to manufacturers, distributors, and consumers about the critical role they play in preserving the efficacy of antimicrobials and safeguarding public health.